Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma - PubMed (original) (raw)
Case Reports
. 1994 May;144(5):889-95.
Affiliations
- PMID: 8178941
- PMCID: PMC1887369
Case Reports
Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma
J A DiGiuseppe et al. Am J Pathol. 1994 May.
Abstract
Mutations in the K-ras oncogene and in the p53 tumor suppressor gene are commonly identified in sporadic cases of pancreatic adenocarcinoma. Although these genes might serve as useful markers for early diagnosis of pancreatic carcinoma in patients at risk for the development of this disease, familial pancreatic carcinomas have not been studied for these mutations. We recently had the opportunity to examine a pancreas prophylactically removed from a patient with a strong family history of pancreatic carcinoma. This gave us the unique opportunity to study the early events in the development of familial adenocarcinoma of the pancreas. Histopathological examination of the pancreas revealed multifocal papillary and nonpapillary mucinous duct hyperplasia. Seven of these foci were microdissected and analyzed for K-ras and p53 mutations. The K-ras mutations were detected by combined mutant-enriched polymerase chain reaction-restriction fragment length polymorphism analysis and characterized further by allele-specific oligonucleotide hybridization. Five of the seven duct lesions harbored activating point mutations in codon 12 of K-ras; a G to A transition was found in four and a G to C transversion in one. In contrast, these lesions did not harbor detectable p53 mutations as determined by denaturing gradient gel electrophoresis of exons 5 to 8, nor was there overexpression of the p53 protein as determined by immunohistochemistry. These findings suggest that mutations in K-ras represent an early event in the pathogenesis of pancreatic carcinoma. In addition, monitoring of patients with a strong family history of pancreatic carcinoma for K-ras mutations may identify patients at risk for the development of invasive carcinoma.
Comment in
- K-ras mutations in pancreatic ductal proliferative lesions.
Klimstra DS, Longnecker DS. Klimstra DS, et al. Am J Pathol. 1994 Dec;145(6):1547-50. Am J Pathol. 1994. PMID: 7992857 Free PMC article. No abstract available.
Similar articles
- Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia.
Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Caldas C, et al. Cancer Res. 1994 Jul 1;54(13):3568-73. Cancer Res. 1994. PMID: 8012983 - K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.
Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL. Hruban RH, et al. Am J Pathol. 1993 Aug;143(2):545-54. Am J Pathol. 1993. PMID: 8342602 Free PMC article. Review. - Molecular genetics of malignant insulinoma.
Pavelic K, Hrascan R, Kapitanovic S, Vranes Z, Cabrijan T, Spaventi S, Korsic M, Krizanac S, Li YQ, Stambrook P, Gluckman JL, Pavelic ZP. Pavelic K, et al. Anticancer Res. 1996 Jul-Aug;16(4A):1707-17. Anticancer Res. 1996. PMID: 8712689 - Significance of K-ras codon 12 point mutation in pancreatic juice in the diagnosis of carcinoma of the pancreas.
Kimura W, Zhao B, Futakawa N, Muto T, Makuuchi M. Kimura W, et al. Hepatogastroenterology. 1999 Jan-Feb;46(25):532-9. Hepatogastroenterology. 1999. PMID: 10228857 Review.
Cited by
- K-ras mutations and allelic loss at 5q and 18q in the development of human pancreatic cancers.
Sugio K, Molberg K, Albores-Saavedra J, Virmani AK, Kishimoto Y, Gazdar AF. Sugio K, et al. Int J Pancreatol. 1997 Jun;21(3):205-17. doi: 10.1007/BF02821606. Int J Pancreatol. 1997. PMID: 9322119 - Quantitative Proteomic Analysis of Differentially Expressed Protein Profiles Involved in Pancreatic Ductal Adenocarcinoma.
Kuo KK, Kuo CJ, Chiu CY, Liang SS, Huang CH, Chi SW, Tsai KB, Chen CY, Hsi E, Cheng KH, Chiou SH. Kuo KK, et al. Pancreas. 2016 Jan;45(1):71-83. doi: 10.1097/MPA.0000000000000388. Pancreas. 2016. PMID: 26262590 Free PMC article. - Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.
Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, Hezel AF, Feng B, Brennan C, Weissleder R, Mahmood U, Hanahan D, Redston MS, Chin L, Depinho RA. Bardeesy N, et al. Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5947-52. doi: 10.1073/pnas.0601273103. Epub 2006 Apr 3. Proc Natl Acad Sci U S A. 2006. PMID: 16585505 Free PMC article. - K-ras mutations in pancreatic ductal proliferative lesions.
Klimstra DS, Longnecker DS. Klimstra DS, et al. Am J Pathol. 1994 Dec;145(6):1547-50. Am J Pathol. 1994. PMID: 7992857 Free PMC article. No abstract available. - Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma.
Slebos RJ, Baas IO, Clement M, Polak M, Mulder JW, van den Berg FM, Hamilton SR, Offerhaus GJ. Slebos RJ, et al. Br J Cancer. 1996 Jul;74(2):165-71. doi: 10.1038/bjc.1996.333. Br J Cancer. 1996. PMID: 8688317 Free PMC article.
References
- Am J Pathol. 1993 Aug;143(2):545-54 - PubMed
- Cancer Res. 1993 Jun 1;53(11):2472-4 - PubMed
- Cancer. 1979 Apr;43(4):1418-28 - PubMed
- Virchows Arch A Pathol Anat Histol. 1980;387(2):221-33 - PubMed
- JAMA. 1982 May 28;247(20):2798-802 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous